The press releases are available in Swedish when no translation exists.
Chordate Medical Holding AB (Publ.) ("Chordate" or "the Company") held an Extraordinary General Meeting on October 5th, 2021, whereby the following main resolutions were made.
In order to counteract the spread of covid-19, the meeting was conducted only by postal vote without physical participation.
Determination of fees to the board and election of the board
The EGM determined that the board fee shall amount to a maximum of SEK 400,000 with the following distribution. The Chairman shall be remunerated with SEK 160,000 and other members who are not employees of the Company shall be remunerated with SEK 80,000 each.
Re-election of the board members Henrik Rammer, Tommy Hedberg, Gunilla Lundmark, and new election of Caroline Lundgren Brandberg.
Long-term incentive program 2021
The EGM agreed to establish a long-term incentive program through a resolution on a directed issue of a maximum of 5,500,000 warrants, entailing an increase in the share capital upon full exercise by a maximum of SEK 1,375,000, in accordance with the Board's proposal. The issue is carried out with the deviation from the shareholders' preferential rights, in accordance with what has been previously communicated, with the purposes that through the introduction of an incentive program, current and future employees and consultants in the Company will be able to become long-term shareholders and work for, and take part of, a positive value development of the share in the Company during the period covered by the proposed program, and that the Company will be able to retain and recruit competent and committed staff.
Full terms and conditions for the above-mentioned proposals are available in full on the company's website: https://www.chordate.com/investor-relations/bolagsstyrning/bolagsstaemma/
Nomination Committee for the 2022 Annual General Meeting
The EGM resolved to establish a Nomination Committee prior to the 2022 Annual General Meeting. The Nomination Committee consists of representatives of the four largest shareholders, namely Isak Brandberg AB (12.1%), HAWOC Investment AB (10.4%), Sifonen (9.1%) and Tommy Hedberg (5.4%).
This disclosure was submitted for publication, through the contact person below, on October 5th, 2021, at 13:30 pm CET.
For more information, please contact:Anders Weilandt, CEOe-mail: firstname.lastname@example.orgCell: +46 733-874277
About Chordate Chordate Medical Holding AB (publ) is a medical technology company that for over ten years has developed, patented and CE-marked a new neuromodulation treatment technology for chronic nasal congestion (rhinitis) and chronic migraine. The company offers its product via distributors to clinics and hospitals in selected European markets, Israel and Saudi Arabia. Chordate Medical's share is listed on the Nordic Growth Market NGM - SME (ticker: CMH). Read more athttps://www.chordate.com/en/
Press releases and reports via E-mail.
We are a Swedish medical technology company listed on Nasdaq First North Growth Market.
Chordate has spent more than 10 years developing the Kinetic Oscillation Stimulation, K.O.S, a technique for treating rhinitis and migraine. We have a patent on K.O.S in the EU and the United States, as well as many other countries.
We have answered frequently asked questions in our FAQ. If you want to know more, please get in touch.
Please note that the MAR rules (Market Abuse Regulation) prohibits us from providing information to individual inquirers regarding matters of the company's share, share price, economy and financials, commercial and scientific activities, and other information that potentially can alter the Market valuation of the traded share. We refer in general to the public information published by the company for such questions. Hence, emails with such questions will not be responded to individually.